United Therapeutics (UTHR) Current Assets (2009 - 2026)

United Therapeutics has disclosed Current Assets across 18 years of filings, most recently posting $3.5 billion for Q2 2026.

• In Q2 2026, Current Assets fell 8.97% year-over-year to $3.5 billion; the TTM figure through Jun 2026 stood at $3.5 billion (down 8.97% YoY), while the FY2025 annual figure was $3.7 billion, down 4.42% from the prior year.
• Current Assets came in at $3.5 billion for Q2 2026 at United Therapeutics, up from $2.9 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $4.0 billion in Q3 2024 to a low of $2.6 billion in Q1 2022.
• Average Current Assets over 5 years is $3.4 billion, with a median of $3.5 billion recorded in 2023.
• Year-over-year, Current Assets surged 45.48% in 2022 and fell 27.1% in 2026.
• Over 5 years, Current Assets stood at $3.4 billion in 2022, then climbed by 5.05% to $3.6 billion in 2023, then gained by 9.09% to $3.9 billion in 2024, then declined by 4.42% to $3.7 billion in 2025, then decreased by 5.91% to $3.5 billion in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $3.5 billion in Q2 2026, $2.9 billion in Q1 2026, and $3.7 billion in Q4 2025.